Health and Healthcare
Why Fluidigm's COVID-19 Saliva-Based Test Is a Huge Hit

Published:
Fluidigm Corp. (NASDAQ: FLDM) made a splash with the markets on Wednesday morning after the company announced a critical update from the U.S. Food and Drug Administration (FDA) in regards to its COVID-19 test.
Fluidigm has received Emergency Use Authorization (EUA) from the FDA for its saliva-based test, the Advanta Dx SARS-CoV-2 RT-PCR Assay. It is designed to be run on the Fluidigm Biomark HD microfluidics platform.
With this approval, the firm helps alleviate the constrained supply chain for testing within the United States. The Biomark HD platform can generate as many as 6,000 test results per day on a single system.
The test is saliva based and therefore less invasive than the standard nasopharyngeal swab. Also, the clinical study associated with the EUA submission demonstrated a 100% agreement between the saliva results from the Advanta Dx SARS-CoV-2 RT-PCR Assay and the results from paired nasopharyngeal samples tested with authorized assays.
The Advanta Dx SARS-CoV-2 RT-PCR Assay was developed in collaboration with scientists at the McDonnell Genome Institute and the Department of Genetics at the Washington University School of Medicine in St. Louis.
Management noted that it has a high degree of confidence that this new test will not only enhance testing capacity but also will significantly improve speed to results and scale. The ease of use for health care providers and patients alike will enable improved testing access to the U.S. and global population.
Excluding Wednesday’s move, Fluidigm stock had vastly outperformed the broad markets with a gain of about 152% year to date. In the past 52 weeks, the share price was closer to 65% higher.
Fluidigm stock traded up about 23% at $10.80, in a 52-week range of $1.17 to $12.45. The consensus price target is $12.67.
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.